X @Bloomberg
Novo Nordisk’s earnings rose less than expected in the second quarter as the Danish drugmaker contends with competition in the crucial US market for obesity drugs https://t.co/v7F9gknCva ...
Novo Nordisk’s earnings rose less than expected in the second quarter as the Danish drugmaker contends with competition in the crucial US market for obesity drugs https://t.co/v7F9gknCva ...